A

    Anika Therapeutics Inc (ANIK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $20.87
    -0.23 (-1.09%)

    Market Cap: $282.38M

    Last updated: Sep 01, 2026 at 4:59 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +9.04%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.17
    Range$0.17 - $0.17
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$0.03-82.4%
    60d ago$0.03-82.4%
    30d ago$0.03-82.4%
    7d ago$0.03-82.4%
    Current$0.17
    Revenue Consensus
    $30M
    Range$29M - $30M
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.85
    Range$0.85 - $0.85
    1 analysts
    Revenue Consensus
    $35M
    Range$35M - $35M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.85---
    Sep 26EST
    		-$0.17---
    Jun 26
    Reported Jul 29
    		$0.30$-0.19+257.89%Beat+330.8%
    Mar 26
    Reported Apr 29
    		$0.27$-0.16+268.75%Beat+550.0%
    Dec 25
    Reported Feb 26
    		$0.13$-0.19+168.42%Beat+192.9%
    Sep 25
    Reported Nov 5
    		$-0.17$-0.19+10.53%Beat+32.0%
    Jun 25
    Reported Jul 30
    		$-0.13$-0.13+0.00%Beat-176.5%
    Mar 25
    Reported May 9
    		$-0.06$0.09-166.67%Miss-166.7%
    Dec 24
    Reported Mar 12
    		$-0.14$-0.11-27.27%Miss+96.7%
    Sep 24
    Reported Oct 31
    		$-0.25$0.30-183.33%Miss+44.4%
    Jun 24
    Reported Aug 8
    		$0.17$0.20-15.00%Miss+183.3%
    Mar 24
    Reported May 8
    		$0.09$0.05+80.00%Beat+125.0%
    Dec 23
    Reported Mar 13
    		$-4.30$-0.26-1553.85%Miss-1164.7%
    Sep 23
    Reported Nov 2
    		$-0.45$-0.35-28.57%Miss-800.0%
    Jun 23
    Reported Aug 8
    		$0.06N/A+118.75%Beat+150.0%
    Mar 23
    Reported May 9
    		$-0.36$-0.32-12.50%Miss-227.3%
    Dec 22
    Reported Mar 6
    		$-0.34$-0.24-41.67%Miss+15.0%
    Sep 22
    Reported Nov 8
    		$-0.05N/A+78.26%Beat-200.0%
    Jun 22
    Reported Aug 3
    		$-0.12$-0.21+42.86%Beat-233.3%
    Mar 22
    Reported May 5
    		$-0.11N/A+64.52%Beat-283.3%
    Dec 21
    Reported Mar 8
    		$-0.40$-0.25-60.00%Miss-433.3%
    Sep 21
    Reported Nov 4
    		$0.05$0.05+0.00%Beat+0.0%
    Jun 21
    Reported Aug 5
    		$0.09$-0.03+400.00%Beat+0.0%
    Mar 21
    Reported May 6
    		$0.06$0.01+500.00%Beat-86.7%
    Dec 20
    Reported Mar 4
    		$0.12$0.14-14.29%Miss-72.1%
    Sep 20
    Reported Nov 4
    		$0.05N/A-61.54%Miss-92.2%
    Jun 20
    Reported Jul 30
    		$0.09$-0.14+164.29%Beat-86.6%
    Mar 20
    Reported May 7
    		$0.45$0.22+104.55%Beat+45.2%
    Dec 19
    Reported Feb 20
    		$0.43$0.42+2.38%Beat-20.4%
    Sep 19
    Reported Oct 24
    		$0.64$0.39+64.10%Beat+20.8%
    Jun 19
    Reported Jul 24
    		$0.67$0.40+67.50%Beat-1.5%
    Mar 19
    Reported May 2
    		$0.31$0.20+55.00%Beat+167.4%
    Dec 18
    Reported Feb 21
    		$0.54$0.33+63.64%Beat+42.1%
    Sep 18
    Reported Oct 24
    		$0.53$0.31+70.97%Beat+15.2%
    Jun 18
    Reported Jul 25
    		$0.68$0.29+134.48%Beat-10.5%
    Mar 18
    Reported May 2
    		$-0.46$0.25-284.00%Miss-224.3%
    Dec 17
    Reported Feb 21
    		$0.38$0.44-13.64%Miss-29.6%
    Sep 17
    Reported Oct 25
    		$0.46$0.42+9.52%Beat-22.0%
    Jun 17
    Reported Jul 26
    		$0.76$0.44+72.73%Beat-
    Mar 17
    Reported May 3
    		$0.37$0.38-2.63%Miss-
    Dec 16
    Reported Feb 15
    		$0.54$0.53+1.89%Beat-
    Sep 16
    Reported Oct 26
    		$0.59$0.47+25.53%Beat-

    Key Metrics

    Valuation
    P/E Ratio39.38EV/EBITDA519.02x
    Price/FCF495.01xFCF Yield0.20%
    Profitability
    Profit Margin-3.14%Operating Margin11.40%
    ROE-2.19%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.48xQuick Ratio3.19x
    Trading Statistics
    Beta0.19Avg Volume139.23K
    52-Week High$22.8852-Week Low$8.37

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.32
    SMA 20$21.08
    SMA 50$17.85
    SMA 200$13.72
    EMA 10$21.13
    EMA 20$20.55
    EMA 50$18.63
    EMA 200$14.99

    MACD

    Line: 0.96Signal: 1.22Hist: -0.26

    ADX

    ADX: 50.6+DI: 23.2-DI: 11.8

    Aroon & PSAR

    Aroon Up40.0
    Aroon DownN/A
    PSAR$22.47

    Bollinger Bands

    Upper Band$22.50
    Lower Band$19.66
    %B Position1347%(Upper)
    Band Width0.43

    RSI (14-Day)

    Neutral
    57.1

    Momentum Oscillators

    Stoch %K26.8
    Stoch %D35.4
    Williams %R-69.1
    ROC (10d)-2.8%
    Momentum-0.60
    CCI (20d)-49.8
    MFI (14d)32.1

    Volatility Measures

    ATR (14d)$1.06(5.1%)
    StdDev (20d)0.71
    Hist Vol48.8%(High)

    Volume Flow

    VWAP$20.77
    OBV3.9M
    AD Line-573.7K
    CMF (20d)-0.048

    Volume Metrics

    Avg Vol (20d)137.0K
    Vol Ratio1.1x
    VWMA (20d)$21.05

    Pivot Points

    R3$22.07
    R2$21.75
    R1$21.43
    Pivot Point$21.11
    S1$20.79
    S2$20.47
    S3$20.15

    Advanced Oscillators

    TSI27.55
    Ultimate Osc43.3
    KST274.14

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$32.61M$29.61M$30.61M$27.82M$28.22M$26.17M$30.60M$29.56M$30.72M$29.02M$-2,899,000$41.47M
    Cost of Revenue$11.37M$10.62M$11.44M$12.23M$13.86M$11.49M$13.48M$10.15M$10.23M$10.05M$-8,672,000$16.52M
    Gross Profit$21.24M$19.00M$19.18M$15.58M$14.36M$14.68M$17.13M$19.41M$20.49M$18.98M$5.77M$24.94M
    Operating Expenses$18.29M$24.48M$18.53M$18.82M$18.54M$18.96M$17.83M$19.49M$22.30M$21.48M$-18,929,000$32.62M
    R&D$7.34M$6.71M$6.45M$6.95M$6.31M$6.06M$6.51M$5.95M$6.68M$6.41M$-3,342,000$7.79M
    SG&A$10.95M$17.77M$12.08M$11.87M$12.23M$12.91M$11.32M$13.54M$15.62M$15.07M$-15,587,000$24.83M
    Operating Income$2.95M$-5,488,000$646,000$-3,233,000$-4,180,000$-4,284,000$-705,000$-81,000$-1,810,000$-2,505,000$24.70M$-7,674,000
    Interest Income$426,000$667,000$118,000$997,000$214,000$415,000$744,000$406,000$595,000$592,000$577,000$635,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$3.38M$-4,821,000$764,000$-2,236,000$-3,966,000$-3,869,000$39,000$325,000$-1,215,000$-1,913,000$25.28M$-7,039,000
    Income Tax Expense$71,000$235,000$-1,037,000$939,000$681,000$89,000$2.52M$2.17M$1.33M$43,000$9.05M$-463,000
    Net Income$3.31M$-5,056,000$292,000$-2,329,000$-3,970,000$-4,873,000$-21,865,000$-29,918,000$-88,000$-4,514,000$-63,000,000$-6,576,000
    EBITDA$4.46M$-4,081,000$1.96M$-1,830,000$-2,764,000$-2,692,000$1.11M$2.11M$248,000$-442,000$28.28M$-5,218,000
    EBIT$2.95M$-5,488,000$646,000$-3,233,000$-4,180,000$-4,284,000$-705,000$-81,000$-1,810,000$-2,505,000$24.70M$-7,674,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANIK

    News

    Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

    Anika Therapeutics (ANIK) has seen its stock price increase by 43.4% over the past three months, driven by investor confidence in its commercial products, pipeline, and improved financial outlook. The company's diversified portfolio includes osteoarthritis pain management and regenerative solutions, with strong performance in both commercial and OEM channels. Anika has also raised its 2026 financial guidance while adopting a more conservative approach for 2027.

    TradingView•8/21/26•
    Bullish

    Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why

    Anika Therapeutics (NASDAQ:ANIK) stock recently surpassed its 200-day moving average of $14.84, closing at $21.26, despite a 1.4% dip during the session. Analyst sentiment has improved, with B. Riley raising its price target to $21 and Wall Street Zen and Zacks upgrading the stock to "strong buy," resulting in an overall "Moderate Buy" rating. The company also reported strong quarterly earnings, beating expectations with $0.42 EPS on $32.61 million in revenue.

    MarketBeat•8/20/26•
    Bullish

    Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO

    This article highlights five stocks—OptimumBank Holdings Inc. (OPHC), EuroDry Ltd. (EDRY), Enova International Inc. (ENVA), Anika Therapeutics Inc. (ANIK), and The GEO Group Inc. (GEO)—that have shown recent price strength and are poised to continue their upward momentum. Following a strong performance by major U.S. stock indexes in early August, these companies are identified as having solid reasons for their bull runs and strong expected earnings growth. The article emphasizes using additional parameters beyond just price strength for a successful investment strategy.

    Yahoo Finance•8/11/26•
    Bullish

    Understanding Momentum Shifts in (ANIK)

    This article analyzes Anika Therapeutics Inc. (ANIK) using AI models, highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, alongside a multi-timeframe signal analysis. The report emphasizes the role of AI in providing real-time signals, risk management, and personalized alerts for investors.

    Stock Traders Daily•8/8/26•
    Bullish

    Anika Therapeutics, Inc. (ANIK) stock price, news, quote and history

    This Yahoo Finance page provides comprehensive financial data for Anika Therapeutics, Inc. (ANIK), a company specializing in early intervention orthopedics. It includes current stock price, performance metrics, key statistics, earnings trends, analyst ratings, and a company overview detailing its product offerings in osteoarthritis pain management and regenerative solutions. The stock closed at $21.42, up 6.25%, with strong year-to-date and 1-year returns.

    Yahoo Finance UK•8/8/26•
    Somewhat-Bullish

    Frequently Asked Questions About ANIK

    Does ANIK pay dividends?
    Anika Therapeutics Inc (ANIK) does not currently pay a regular dividend.
    What is ANIK's P/E ratio?
    Anika Therapeutics Inc has a price-to-earnings (P/E) ratio of 39.38.
    What is ANIK's market cap?
    Anika Therapeutics Inc (ANIK) has a market capitalization of $282.38M with a current stock price of $20.87.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In